Literature DB >> 32573468

Quantification of plasma remdesivir and its metabolite GS-441524 using liquid chromatography coupled to tandem mass spectrometry. Application to a Covid-19 treated patient.

Jean-Claude Alvarez1, Pierre Moine2, Isabelle Etting3, Djillali Annane2, Islam Amine Larabi3.   

Abstract

Objectives: A method based on liquid chromatography coupled to triple quadrupole mass spectrometry detection using 50 µL of plasma was developed and fully validated for quantification of remdesivir and its active metabolites GS-441524.
Methods: A simple protein precipitation was carried out using 75 µL of methanol containing the internal standard (IS) remdesivir-13C6 and 5 µL ZnSO4 1 M. After separation on Kinetex® 2.6 µm Polar C18 100A LC column (100 × 2.1 mm i.d.), both compounds were detected by a mass spectrometer with electrospray ionization in positive mode. The ion transitions used were m/z 603.3 → m/z 200.0 and m/z 229.0 for remdesivir, m/z 292.2 → m/z 173.1 and m/z 147.1 for GS-441524 and m/z 609.3 → m/z 206.0 for remdesivir-13C6.
Results: Calibration curves were linear in the 1-5000 μg/L range for remdesivir and 5-2500 for GS-441524, with limit of detection set at 0.5 and 2 μg/L and limit of quantification at 1 and 5 μg/L, respectively. Precisions evaluated at 2.5, 400 and 4000 μg/L for remdesivir and 12.5, 125, 2000 μg/L for GS-441524 were lower than 14.7% and accuracy was in the [89.6-110.2%] range. A slight matrix effect was observed, compensated by IS. Higher stability of remdesivir and metabolite was observed on NaF-plasma. After 200 mg IV single administration, remdesivir concentration decrease rapidly with a half-life less than 1 h while GS-441524 appeared rapidly and decreased slowly until H24 with a half-life around 12 h. Conclusions: This method would be useful for therapeutic drug monitoring of these compounds in Covid-19 pandemic.

Entities:  

Keywords:  Covid-19; GS-441524; LC–MS/MS; remdesivir

Mesh:

Substances:

Year:  2020        PMID: 32573468     DOI: 10.1515/cclm-2020-0612

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  11 in total

1.  Eco-friendly stability-indicating HPTLC micro-determination of the first FDA approved SARS-CoV-2 antiviral prodrug Remdesivir: Study of degradation kinetics and structural elucidation of the degradants using HPTLC-MS.

Authors:  Amira H Abo-Gharam; Dina S El-Kafrawy
Journal:  Sustain Chem Pharm       Date:  2022-06-14

2.  Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient's plasma.

Authors:  Aml A Emam; Eglal A Abdelaleem; Esraa H Abdelmomen; Refaat H Abdelmoety; Rehab M Abdelfatah
Journal:  Microchem J       Date:  2022-05-13       Impact factor: 5.304

3.  Development and validation of a paper spray mass spectrometry method for the rapid quantitation of remdesivir and its active metabolite, GS-441524, in human plasma.

Authors:  Christine Skaggs; Hannah Zimmerman; Nicholas Manicke; Lindsey Kirkpatrick
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2022-06-11

4.  Rapid determination of remdesivir (SARS-CoV-2 drug) in human plasma for therapeutic drug monitoring in COVID-19-Patients.

Authors:  Raghavendra Rao Pasupuleti; Pei-Chien Tsai; Vinoth Kumar Ponnusamy; Arivalagan Pugazhendhi
Journal:  Process Biochem       Date:  2020-12-25       Impact factor: 3.757

5.  A combined assay for quantifying remdesivir and its metabolite, along with dexamethasone, in serum.

Authors:  Andrew Reckers; Alan H B Wu; Chui Mei Ong; Monica Gandhi; John Metcalfe; Roy Gerona
Journal:  J Antimicrob Chemother       Date:  2021-04-17       Impact factor: 5.790

6.  Quantitative HPLC-MS/MS determination of Nuc, the active metabolite of remdesivir, and its pharmacokinetics in rat.

Authors:  Ping Du; Guoyong Wang; Song Yang; Pengfei Li; Lihong Liu
Journal:  Anal Bioanal Chem       Date:  2021-07-24       Impact factor: 4.142

7.  Environmental impact of the reported chromatographic methods for the determination of the first FDA-Approved therapy for COVID-19 Patients, Remdesivir: A comparative study.

Authors:  Amal B Ahmed; Mohammed Gamal; Ibrahim A Naguib; Hazim M Ali; Fatma F Abdallah
Journal:  Microchem J       Date:  2022-01-30       Impact factor: 4.821

8.  Exploration for the effect of renal function and renal replacement therapy on pharmacokinetics of remdesivir and GS-441524 in patients with COVID-19: A limited case series.

Authors:  Pyoeng Gyun Choe; Sae Im Jeong; Chang Kyung Kang; Liju Yang; SeungHwan Lee; Joo-Youn Cho; Seung Seok Han; Dong Ki Kim; Sang Min Lee; Wan Beom Park; Myoung-Don Oh; Nam Joong Kim
Journal:  Clin Transl Sci       Date:  2021-11-20       Impact factor: 4.438

9.  Comparative Greenness Metric Estimates for Content Uniformity Testing of Anti-Cov-2, GS-5734 in Commercial Vials: Validated Micellar Electrokinetic Chromatographic Assay.

Authors:  Sohila M Elonsy; Miranda F Kamal; Mohamed M A Hamdy; Mona M Abdel Moneim
Journal:  J AOAC Int       Date:  2022-04-27       Impact factor: 2.028

10.  Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs "Remdesivir and Favipiravir": Green assessment with application to pharmaceutical formulations and human plasma.

Authors:  Deena A M Noureldeen; John M Boushra; Adel S Lashien; Ahmed F Abdel Hakiem; Tamer Z Attia
Journal:  Microchem J       Date:  2021-12-18       Impact factor: 4.821

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.